Literal source text
Lobbying issues and bill citations
HCR · Health Issues
Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), insulin price cap, VICP Program, and PBM reform; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act.
Literal federal measure citations: S.891
BUD · Budget/Appropriations
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
Literal federal measure citations: H.R.1968, H.Con.Res.14
MMM · Medicare/Medicaid
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
CPT · Copyright/Patent/Trademark
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
TRD · Trade (domestic/foreign)
Issues related to pharmaceutical IP, supply chain, and tariffs.
TAX · Taxation/Internal Revenue Code
Issues related to tax reform. Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit.
